fluordopa (18 F)
Image for illustration purposes only.
A radiopharmaceutical indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum; it is used in the evaluation of adult patients with suspected Parkinsonian syndromes (PS). A PET scan with (¹⁸F)fluordopa is a complementary test to other diagnostic evaluations.
Produced and distributed by the following units:
Itupeva, São Paulo (Official Letter No. 1463362251)
- Presentation: Blister pack containing 1 multidose vial.
- Dosage form: Solution for injection.
- Route of administration: Intravenous.
- Composition: Each vial of radiopharmaceutical contains: fluordopa (18F) 185 to 400 MBq.
- Excipientes com efeito conhecido: Cada mL de solução contém até 2 mg de etanol e até 3,51 mg de sódio por dose.
- Physical half-life: ~ 110 minutes
- Indications: To aid in the diagnosis of adult patients with suspected parkinsonian syndromes.
R2Pharma products are available only by means of medical prescription from a licensed physician.
IF SYMPTOMS PERSIST, CONSULT A DOCTOR.
Contraindications, warnings, adverse reactions, drug interactions, precautions, and dosage: see the package insert.
The content on this page is intended for healthcare professionals.
***In the first phase, supply will be provided exclusively to customers located in the following cities: Campinas, Jundiaí, Piracicaba, Sorocaba, São Paulo (capital), São José dos Campos, and São Carlos.